This biotech company's shares are on a tear – again – after another contract win

A new contract with a prestigious US institution spells good news for shareholders.

Key points
  • 4D Medical has announced another major contract win with a pre-eminent health system in the US.
  • It is the fourth such contract win since the company received Food and Drug Administration clearance just more than four months ago.
  • The company's founder and Managing Director says 4D was building "unstoppable momentum''.  

4D Medical Ltd (ASX: 4DX) has secured a contract with UC San Diego Health – one of the US's pre-eminent academic health systems – to use its CT:VQ technology for clinical use in lung imaging.

Shares in the biotechnology company jumped on the news, trading 9.3% higher at $4.58 – not far off their record high of $4.65 – in early trade on Wednesday.

Medical workers examine an x-ray or scan in a hospital laboratory.

Image source: Getty Images

Prestigious institution

4D Medical said in a statement to the ASX that UC San Diego Health (UCSD) was "one of the nation's leading academic health systems and has consistently ranked in the top 10 in the US for pulmonary and lung surgery''.

The company added:

UCSD has commenced clinical use of CT:VQ under a structured launch framework whereby introductory pricing will apply through March 31, supporting early clinical adoption and workflow establishment, before transitioning to full commercial terms. UCSD joins Stanford University, University of Miami, and Cleveland Clinic as the fourth U.S. academic medical centre (AMC) to deploy CT:VQ™ for clinical use. This expanding network of leading AMCs powers 4DMedical's strategic approach of establishing reference sites at the nation's most prestigious institutions, creating a powerful foundation for broader market adoption.

4D Medical said it had been slightly more than four months since it received US Food and Drug Administration clearance to market its technology, and in that time, it had secured contracts with four of the most respected academic medical centres in the US.

The company added:

These deployments demonstrate the compelling clinical value proposition of CT:VQ™: eliminating the need for radioisotope and contrast administration, providing superior image resolution compared to nuclear medicine, seamlessly integrating into existing CT imaging workflows, and enabling access to reimbursement pathways that support sustainable clinical adoption.

Strong momentum

4D Medical founder and Managing Director Andreas Fouras said the new contract win was a "powerful validation'' of the company's technology.

He added:

In just over four months since FDA clearance, we've established CT:VQ™ at four of America's leading academic medical centres: Stanford, University of Miami, Cleveland Clinic, and now UCSD. This rapid adoption by elite institutions demonstrates both the transformative potential of CT:VQ™ and the strength of our go-to-market execution. These prestigious AMCs serve as powerful anchors for our commercialisation strategy. Combined with our Philips partnership and growing commercial pipeline, we are building unstoppable momentum as we establish CT:VQ™ as the new standard of care in pulmonary imaging.  

4D Medical was valued at $2.2 billion at the close of trade on Tuesday. The company has increased in value almost 20-fold over the past 12 months, from lows of just 22.5 cents.

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »